Skip to content
DraconiticResearch
Search Sources API
194,164 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY-NC-NDCancer medicine

Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population-Based Analysis.

  • Mengyang Di1,2,3
  • Scott F Huntington4,5
  • Jenna M Voutsinas6
  • Vicky Q Wu6
  • Chaitra S Ujjani1,2
  • Scott D Ramsey3
  • Jennifer J Huang1,2
  • Ajay K Gopal1,2
  • Mazyar Shadman1,2
6 affiliations
  1. 1Division of Hematology-Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
  2. 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  3. 3Fred Hutchinson Cancer Center, Hutchinson Institute for Cancer Outcomes Research, Seattle, Washington, USA.
  4. 4Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  5. 5Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, Connecticut, USA.
  6. 6Statistics Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Read full textPDFDOICite

Abstract

Chemoimmunotherapy (CIT) had long been used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) until 2014 when the first novel agent, ibrutinib, was approved in the United States. Numerous novel therapies have since become available. Nevertheless, as novel therapies have largely replaced CIT in CLL/SLL, its impact on survival has yet to be examined on the population level. In this study, we used the SEER (Surveillance, Epidemiology, and End Results) database to compare survival in patients with CLL/SLL before and after the approval of the first novel therapy. We included 9913 patients who started treatment within 2 years of CLL/SLL diagnosis. In the multivariable analyses, the overall survival improved significantly (hazard ratio [HR]: 0.86, 95% confidence interval: 0.81, 0.92), and death from CLL/SLL and other cancer (subdistribution-HR: 0.69 and 0.77) also decreased significantly. Nevertheless, CLL/SLL remains the main cause of death during the novel agent era.

Related

  1. Integration of gene expression and alternative splicing enhances IGHV mutation status and survival risk prediction in chronic lymphocytic leukemia
    Lei Yu, Ruidong Li, Meiling Jin +5
    Scientific ReportsPeer-reviewedCC BYFull textHuman geneticsDOAJ
  2. Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL‐2 Inhibitors
    Finn J. Schulze, Evgenii Shumilov, Akhil Behringer +6
    Cancer MedicinePeer-reviewedCC BYFull textHuman geneticsDOAJ
  3. A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report
    Mostafa Kamandi, Mohammad Mahdi Alvandi Fard
    Clinical case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. An Atypical Presentation of Richter's Transformation in Chronic Lymphocytic Leukemia: Stroke-Like Onset With Multiorgan Involvement Including the Heart and Seminal Vesicles
    Aysha Musthafa, Gayatri Gopan
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. [Chronic lymphocytic leukemia presenting initially as purpura nephritis: a case report].
    M W Tong, W X Nong, D Q Zhang +1
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiPeer-reviewedCC BYFull textHuman geneticsEurope PMC

Cite

BibTeXRIS
BibTeX
@article{di2026survival,
  title = {{Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population-Based Analysis.}},
  author = {Mengyang Di and Scott F Huntington and Jenna M Voutsinas and Vicky Q Wu and Chaitra S Ujjani and Scott D Ramsey and Jennifer J Huang and Ajay K Gopal and Mazyar Shadman},
  journal = {Cancer medicine},
  year = {2026},
  month = oct,
  doi = {10.1002/cam4.72408},
  url = {https://europepmc.org/article/MED/42897340},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population-Based Analysis.
AU  - Mengyang Di
AU  - Scott F Huntington
AU  - Jenna M Voutsinas
AU  - Vicky Q Wu
AU  - Chaitra S Ujjani
AU  - Scott D Ramsey
AU  - Jennifer J Huang
AU  - Ajay K Gopal
AU  - Mazyar Shadman
PY  - 2026
DA  - 2026/10/01
JO  - Cancer medicine
DO  - 10.1002/cam4.72408
UR  - https://europepmc.org/article/MED/42897340
AB  - Chemoimmunotherapy (CIT) had long been used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) until 2014 when the first novel agent, ibrutinib, was approved in the United States. Numerous novel therapies have since become available. Nevertheless, as novel therapies have largely replaced CIT in CLL/SLL, its impact on survival has yet to be examined on the population level. In this study, we used the SEER (Surveillance, Epidemiology, and End Results) database to compare survival in patients with CLL/SLL before and after the approval of the first novel therapy. We included 9913 patients who started treatment within 2 years of CLL/SLL diagnosis. In the multivariable analyses, the overall survival improved significantly (hazard ratio [HR]: 0.86, 95% confidence interval: 0.81, 0.92), and death from CLL/SLL and other cancer (subdistribution-HR: 0.69 and 0.77) also decreased significantly. Nevertheless, CLL/SLL remains the main cause of death during the novel agent era.
SN  - 2045-7634
ER  -